- SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform
- In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure
- SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations
- It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits
SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its revolutionary ABBIE platform. This marks a significant milestone for SOHM, notably as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits through licensing opportunities as early as 2024 (https://ibn.fm/ZM4JH).
UACI expressed optimism in the arrangement, citing their confidence in ABBIE thriving through the…
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
